ABOS
Acumen Pharmaceuticals, Inc.
Key Financials
Net Income
$-121335000
↓ 18.6%
Operating Income
$-123832000
↓ 8.6%
EPS (Diluted)
$-2.00
↓ 17.0%
Total Liabilities
$52.4M
↓ 8.3%
Shareholders' Equity
$70.4M
↓ 61.3%
Total Assets
$122.8M
↓ 48.6%
Long-term Debt
$22.4M
↓ 23.9%
Cash & Equivalents
$54.0M
↑ 51.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 6/16/2026 | View on SEC |
| 8-K | 6/16/2026 | View on SEC |
| 144 | 6/15/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
| 144 | 6/9/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ABOS |
| Company Name | Acumen Pharmaceuticals, Inc. |
| CIK | 1576885 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-344-4190 |